About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01351909

Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer

Study identifier: NCT01351909
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Phase I: breast cancer that is HER2/neu negative
  • Phase II: ER and PR positive and HER2/neu negative
  • No prior PARP inhibitor treatment (both phases)

Type of study:

Phase I/II study

Treatment:

Participants will be in one of two groups:

  • 21-day cycles with cyclophosphamide and veliparib orally on days 1-21
  • 21-day cycles with cyclophosphamide and a placebo orally on days 1-21

Study sites:

Connecticut
Farmington
University of Connecticut
Contact: Susan H. Tannenbaum 860-679-2474 stannenbaum@uchc.edu

New York
Bronx
Montefiore Medical Center
Contact: Eleni Andreopoulou 718-904-2555 eandreop@montefiore.org

Brooklyn
Maimonides Medical Center
Contact: Susan Burdette-Radoux 718-765-2644 sburdette-radoux@maimonides.org

New York
Columbia University Medical Center
New York, New York, United States, 10032
Contact: Kevin M. Kalinsky 212-305-8615 kk2693@columbia.edu

Mount Sinai Medical Center
Contact: George Raptis 212-241-6631

New York University Langone Medical Center
Contact: Yelena Novik 212-731-5350 yelena.novik@med.nyu.edu

Weill Medical College of Cornell University
Contact: Tessa Cigler 212-821-0644 tec9002@med.cornell.edu

Ohio
Columbus
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Contact: Bhuvaneswari Ramaswamy 614-293-6401 bhuvaneswari.ramaswamy@osumc.edu

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org